SG11201407995RA - Stabilized gp120 - Google Patents
Stabilized gp120Info
- Publication number
- SG11201407995RA SG11201407995RA SG11201407995RA SG11201407995RA SG11201407995RA SG 11201407995R A SG11201407995R A SG 11201407995RA SG 11201407995R A SG11201407995R A SG 11201407995RA SG 11201407995R A SG11201407995R A SG 11201407995RA SG 11201407995R A SG11201407995R A SG 11201407995RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- emeryville
- diagnostics
- novartis
- novartis vaccines
- Prior art date
Links
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661050P | 2012-06-18 | 2012-06-18 | |
| PCT/EP2013/062553 WO2013189901A1 (en) | 2012-06-18 | 2013-06-17 | Stabilized gp120 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407995RA true SG11201407995RA (en) | 2015-01-29 |
Family
ID=48628698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407995RA SG11201407995RA (en) | 2012-06-18 | 2013-06-17 | Stabilized gp120 |
Country Status (14)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| US10010605B2 (en) * | 2014-09-23 | 2018-07-03 | Merial, Inc. | FMDV recombinant vaccines and uses thereof |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3426291A1 (en) | 2016-03-09 | 2019-01-16 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| MX2019004681A (es) | 2016-10-21 | 2019-10-07 | Altor Bioscience Corp | Moleculas basadas en il-15 multimericas. |
| EP3697440A1 (en) | 2017-10-16 | 2020-08-26 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| CN109851664A (zh) * | 2017-11-30 | 2019-06-07 | 清华大学 | 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用 |
| MX2020013621A (es) | 2018-06-19 | 2021-03-25 | Nantcell Inc | Composiciones y metodos de tratamiento de vih. |
| WO2021249013A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Vaccine compositions, methods, and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2786488B1 (fr) * | 1998-11-27 | 2003-04-25 | Orstom | Mutants de la gp120 et leurs applications biologiques |
| WO2001000648A1 (en) * | 1999-06-25 | 2001-01-04 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| JP2010536885A (ja) * | 2007-08-24 | 2010-12-02 | ノバルティス アーゲー | Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質 |
| US9175070B2 (en) * | 2009-09-25 | 2015-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
-
2013
- 2013-06-17 US US14/408,466 patent/US20150183835A1/en not_active Abandoned
- 2013-06-17 AU AU2013279456A patent/AU2013279456A1/en not_active Abandoned
- 2013-06-17 MX MX2014014682A patent/MX2014014682A/es unknown
- 2013-06-17 EP EP13729364.3A patent/EP2861249A1/en not_active Withdrawn
- 2013-06-17 CA CA2876762A patent/CA2876762A1/en not_active Abandoned
- 2013-06-17 JP JP2015516648A patent/JP2015521592A/ja active Pending
- 2013-06-17 CN CN201380032027.2A patent/CN104619338A/zh active Pending
- 2013-06-17 IN IN2740KON2014 patent/IN2014KN02740A/en unknown
- 2013-06-17 KR KR20157000850A patent/KR20150023735A/ko not_active Withdrawn
- 2013-06-17 RU RU2015101081A patent/RU2015101081A/ru not_active Application Discontinuation
- 2013-06-17 WO PCT/EP2013/062553 patent/WO2013189901A1/en not_active Ceased
- 2013-06-17 SG SG11201407995RA patent/SG11201407995RA/en unknown
-
2014
- 2014-11-25 IL IL235898A patent/IL235898A0/en unknown
- 2014-12-02 ZA ZA2014/08840A patent/ZA201408840B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150023735A (ko) | 2015-03-05 |
| AU2013279456A1 (en) | 2014-12-18 |
| WO2013189901A1 (en) | 2013-12-27 |
| IL235898A0 (en) | 2015-01-29 |
| ZA201408840B (en) | 2016-08-31 |
| JP2015521592A (ja) | 2015-07-30 |
| IN2014KN02740A (cg-RX-API-DMAC10.html) | 2015-05-08 |
| CA2876762A1 (en) | 2013-12-27 |
| MX2014014682A (es) | 2015-03-04 |
| US20150183835A1 (en) | 2015-07-02 |
| CN104619338A (zh) | 2015-05-13 |
| RU2015101081A (ru) | 2016-08-10 |
| EP2861249A1 (en) | 2015-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903908PA (en) | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | |
| SG11201804398XA (en) | Method for producing rna molecule compositions | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201806829TA (en) | 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
| SG11201406943XA (en) | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201408396QA (en) | Improved resid hydrotreating catalyst containing titania | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |